Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

July 31, 2019

Study Completion Date

June 30, 2020

Conditions
Mucosal Melanoma
Interventions
DRUG

CM082 plus JS001

CM082:200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AnewPharma

INDUSTRY

NCT03602547 - Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | Biotech Hunter | Biotech Hunter